RTW INVESTMENTS, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001493215

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 81 positions · Total reported value $9.91B · Top-10 concentration 43.5% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 37.2% · 10 new · 12 cut · 13 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.3% · vs SPY -9.4% · Prev Value $11.71B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.7% · vs SPY -3.9% · Latest Value $9.91B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, RTW INVESTMENTS, LP disclosed 81 equity positions with a combined reported value of $9.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 43.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PTGX ($713.07M), ARGX ($682.35M), CGON ($603.60M). By sector, the heaviest allocations are Health Care 99.0%, Industrials 0.5%.

Versus the prior quarter, RTW INVESTMENTS, LP opened 10 new positions, trimmed 12 and fully exited 13, a turnover rate of 37.2% of positions. The portfolio's overlap with the prior quarter was 76% of names.

The largest new positions opened in Q3 2026 were VRDN ($102.03M), ANIX ($28.06M), PYXS ($15.16M).

Of the 13 positions fully exited versus the prior quarter, the largest were ALKS ($87.62M), DFTX ($18.82M), IDYA ($13.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VRDN VIRIDIAN THERAPEUTICS INC · $102.03M
  • ANIX ANIXA BIOSCIENCES INC · $28.06M
  • PYXS PYXIS ONCOLOGY INC · $15.16M
  • SRZN SURROZEN INC · $12.66M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $11.69M
  • SLN SILENCE THERAPEUTICS PLC · $7.65M
  • VNDA VANDA PHARMACEUTICALS INC · $5.98M
  • DYN DYNE THERAPEUTICS INC · $4.83M

Fully Exited (vs previous quarter)

  • ALKS ALKERMES PLC · prev qtr: $87.62M
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $18.82M
  • IDYA IDEAYA BIOSCIENCES INC · prev qtr: $13.80M
  • ATAI ATAI LIFE SCIENCES NV · prev qtr: $10.54M
  • TENX TENAX THERAPEUTICS INC · prev qtr: $10.14M
  • PCSC PERCEPTIVE CAP SOLUTIONS COR · prev qtr: $8.08M
  • WVE WAVE LIFE SCIENCES INC · prev qtr: $7.84M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · prev qtr: $6.33M

Insider Transactions (Form 4)

Latest RTW INVESTMENTS, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-09 Buy Orchestra BioMed Holdings, Inc. 1,200,000 $5.00 SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 1,771 — SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 19,934 — SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 161,807 — SEC filing
2026-07-21 J ALLURION TECHNOLOGIES, INC. 209,254 — SEC filing
2026-04-27 Sell Orchestra BioMed Holdings, Inc. 32 $4.13 SEC filing
2026-04-27 Opt exercise Orchestra BioMed Holdings, Inc. 1,250,032 $0.00 SEC filing
2026-04-20 Buy Kailera Therapeutics, Inc. 500,000 $16.00 SEC filing

All insider transactions →

Fund Profile

RTW Investments, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 81 positions worth $9.91B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-78183 (status: Approved), registered 2013-06-13
  • Regulatory AUM (Form ADV): $14.14B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: rtwfunds.com

Portfolio Structure

  • 81 positions · $9.91B reported value (Q3 2026)
  • Top 10 holdings = 43.5% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 7.2%
  • Average position size: $122.34M

Sector Tilt

  • Health Care 99.0%
  • Industrials 0.5%
  • Information Technology 0.5%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 10 new, 17 added, 12 reduced, 13 exited
  • 42 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to biotech/healthcare (all top-10 holdings are Health Care), with net additions (4 adds vs. 3 reductions in top-10), suggesting bullish sentiment on innovative therapeutics. Weight increases in most holdings indicate confidence in pipeline catalysts or sector momentum. 2. Key moves: - Added: IRTC (+42.9% shares), TNGX (+1.1% shares), ERAS (+25.1% shares), TARS (+3.8% shares). - Reduced: INSM (-36.1% shares), SYRE (-13.2% shares), RDNT (-4.5% shares). - No change: PTGX, ARGX, CGON (held steady). 3. Portfolio structure: Active, high-conviction (concentrated top-10 holdings = 36.47% of AUM), with heavy bias toward clinical-stage biotech (elevated risk/reward). 4. Per-holding one-liner: - PTGX: Protagonist Therapeutics (unverified) – peptide-based therapeutics. - ARGX: Argenx (unverified) – autoimmune disease treatments. - CGON: CG Oncology (unverified) – immuno-oncology therapies. - IRTC: iRhythm (unverified) – wearable cardiac monitoring. - INSM: Insmed (unverified) – rare lung disease drugs. - TNGX: Tango Therapeutics (unverified) – oncology targeted therapies. - ERAS: Erasca (unverified) – cancer drug development. - SYRE: Spyre Therapeutics (unverified) – immunology pipeline. - RDNT: Radnet (unverified) – diagnostic imaging services. - TARS: Tarsus Pharmaceuticals (unverified) – eye disease treatments. 5. Style summary: Aggressive biotech fund with selective additions to high-growth clinical-stage names and reductions in overexposed positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 03:54

Sector Allocation

Health Care 99.0%
Technology 0.5%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.06M $713.07M 7.20%
7.20%
Hold
2 711.58K $682.35M 6.89%
6.89%
Hold
3 8.51M $603.60M 6.09%
6.09%
Hold
4 3.12M $354.50M 3.58%
3.58%
Add
5 3.10M $353.44M 3.57%
3.57%
Reduce
6 14.05M $350.51M 3.54%
3.54%
Add
7 22.45M $329.07M 3.32%
3.32%
Add
8 3.69M $328.68M 3.32%
3.32%
Reduce
9 4.63M $319.24M 3.22%
3.22%
Reduce
10 3.48M $273.88M 2.76%
2.76%
Add
11 10.35M $272.64M 2.75%
2.75%
Add
12 1.39M $266.32M 2.69%
2.69%
Add
13 1.48M $264.16M 2.67%
2.67%
Hold
14 3.30M $262.81M 2.65%
2.65%
Hold
15 3.14M $261.45M 2.64%
2.64%
Hold
16 600.00K $247.99M 2.50%
2.50%
Reduce
17 2.86M $188.63M 1.90%
1.90%
Hold
18 4.54M $184.62M 1.86%
1.86%
Hold
19 2.67M $171.06M 1.73%
1.73%
Hold
20 6.83M $170.35M 1.72%
1.72%
Add
21 312.82K $157.65M 1.59%
1.59%
Reduce
22 4.87M $147.51M 1.49%
1.49%
Hold
23 5.62M $146.21M 1.48%
1.48%
Hold
24 7.14M $143.96M 1.45%
1.45%
Hold
25 1.49M $141.06M 1.42%
1.42%
Hold
26 5.93M $139.33M 1.41%
1.41%
Hold
27 10.95M $136.20M 1.37%
1.37%
Add
28 942.68K $133.71M 1.35%
1.35%
Reduce
29 8.53M $128.20M 1.29%
1.29%
Add
30 10.78M $123.07M 1.24%
1.24%
Hold
31 715.33K $121.48M 1.23%
1.23%
Hold
32 13.52M $118.72M 1.20%
1.20%
Add
33 8.49M $112.43M 1.14%
1.14%
Add
34 3.18M $107.35M 1.08%
1.08%
Hold
35 1.62M $104.67M 1.06%
1.06%
Reduce
36 4.98M $102.03M 1.03%
1.03%
New
37 2.78M $98.71M 1.00%
1.00%
Hold
38 3.94M $95.23M 0.96%
0.96%
Hold
39 2.31M $73.93M 0.75%
0.75%
Hold
40 2.28M $71.36M 0.72%
0.72%
Add
41 1.66M $69.56M 0.70%
0.70%
Add
42 13.56M $66.04M 0.67%
0.67%
Hold
43 9.56M $59.44M 0.60%
Form 4 · 1 →
0.60%
Hold
44 6.72M $54.08M 0.55%
0.55%
Add
45 230.00K $50.96M 0.51%
0.51%
Hold
46 500.00K $48.62M 0.49%
0.49%
Hold
47 17.69M $46.52M 0.47%
0.47%
Hold
48 5.91M $42.70M 0.43%
0.43%
Add
49 1.51M $42.08M 0.42%
0.42%
Add
50 2.36M $36.29M 0.37%
0.37%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 26% of its Top-10 each quarter and backtests at F1 72% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 72% · recall 72% · F1 72% · avg rank error 2.3 · Top-10 turnover 26%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% RCKT · IMCR · MRTX · AXSM · ACAD · RARE · ALNY · ARGX · BRKR · MDGL RCKT · IMCR · AXSM · RARE · BRKR · ARGX · ACAD · NTRA · PTCT · MASI
2024-Q2 50% 50% 50% RCKT · IMCR · AXSM · RARE · BRKR · ARGX · ACAD · NTRA · PTCT · MASI MDGL · RCKT · AXSM · RNAM · ARGX · NTRA · MRUS · INSM · PTCT · DYN
2024-Q3 70% 70% 70% MDGL · RCKT · AXSM · RNAM · NTRA · ARGX · INSM · MRUS · DYN · ACAD MDGL · AXSM · RNAM · ARGX · NTRA · RCKT · PTCT · DYN · PTGX · BRKR
2024-Q4 80% 80% 80% MDGL · RNAM · AXSM · ARGX · NTRA · RCKT · DYN · PTCT · INSM · PTGX MDGL · ARGX · NTRA · AXSM · PTCT · RNAM · RCKT · ALKS · SYK · PTGX
2025-Q1 70% 70% 70% MDGL · ARGX · NTRA · AXSM · PTCT · SYK · RNAM · RCKT · ALKS · PTGX MDGL · ARGX · PTCT · NTRA · AXSM · AKRO · PTGX · RNAM · PEN · INSM
2025-Q2 80% 80% 80% MDGL · ARGX · PTCT · NTRA · AXSM · AKRO · PTGX · RNAM · PEN · SYK MDGL · NTRA · PTCT · ARGX · PTGX · INSM · AKRO · VRNA · RNAM · SYK
2025-Q3 80% 80% 80% MDGL · NTRA · PTCT · ARGX · PTGX · INSM · VRNA · AKRO · RNAM · SYK MDGL · ARGX · RNAM · PTCT · INSM · PTGX · NTRA · AKRO · QURE · PEN
2025-Q4 70% 70% 70% MDGL · RNAM · ARGX · PTCT · INSM · PTGX · NTRA · QURE · AKRO · PEN MDGL · INSM · PTCT · ARGX · PTGX · NTRA · RDNT · TARS · COGT · PEN
2026-Q1 60% 60% 60% MDGL · INSM · PTCT · ARGX · PTGX · NTRA · COGT · RDNT · TARS · PEN MDGL · INSM · PTGX · PTCT · ARGX · CGON · CELC · TNGX · ERAS · NTRA
2026-Q2 90% 90% 90% MDGL · INSM · CGON · PTGX · PTCT · ARGX · CELC · TNGX · ERAS · RDNT MDGL · ARGX · PTCT · PTGX · CGON · INSM · TNGX · SYRE · CELC · ERAS
2026-Q3 ★ 70% 70% 70% MDGL · CGON · ARGX · PTCT · PTGX · INSM · TNGX · CELC · SYRE · ERAS PTGX · ARGX · CGON · IRTC · INSM · TNGX · ERAS · SYRE · RDNT · TARS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings14 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-8.90%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+8.11%vs benchmark
Barra annualised vol32.4%Model estimate
Realised vol35.7%Annualised in window
Weighted beta0.70Raw exposure
Factor / specific risk62% / 38%Share of variance
Top-10 concentration96.7%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16RTW INVESTMENTS, LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-8.90%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+8.11%Portfolio − benchmark
Arithmetic return sum-8.50%Difference vs compounded is the cross term
Weighted raw beta0.70Weighted holding betas
Realised volatility (annualised)35.68%Daily returns in window
Barra model volatility (annualised)32.39%Factor + specific
Factor share of variance61.6%Barra factors
Specific share of variance38.4%Stock residuals
Reported value$3.28B13F long US equity

2. Return attribution

The -8.50% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +1.96% 23.1%
Momentum & Growth 3 -5.21% -61.3%
Volatility & Tail Risk 7 -1.25% -14.7%
Industry 12 +6.88% 81.0%
Specific 1 -10.88% -128.1%
Return attribution (style + industry, %)-9.0-4.5+0.0+4.5+9.0Max Drawdown-0.24Turnover+0.69Beta-0.76Amihud Illiquidity-0.81Leverage (Downside Vol)+0.89Non-linear Size+1.66Mid Cap-1.97Size+2.43Skewness-4.81Residual Volatility+4.82Momentum-5.26Health Care+6.88Kurtosis+7.19Historical Volatility-8.33
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +0.96 +7.51% +7.19% 84.6%
Health Care Industry +0.98 +6.98% +6.88% 80.9%
Residual Volatility Style +1.46 +3.29% +4.82% 56.8%
Size Style -1.25 -1.95% +2.43% 28.6%
Non-linear Size Style +1.65 +1.01% +1.66% 19.6%
Leverage (Downside Vol) Style -0.52 -1.71% +0.89% 10.5%
Turnover Style -0.14 -4.80% +0.69% 8.1%
Growth Style +0.09 +1.75% +0.15% 1.8%
Short-term Reversal Style -0.11 +0.87% -0.10% -1.1%
Max Drawdown Style +0.14 -1.76% -0.24% -2.9%
Beta Style -0.17 +4.44% -0.76% -9.0%
Amihud Illiquidity Style +1.81 -0.45% -0.81% -9.5%
Mid Cap Style +1.02 -1.94% -1.97% -23.2%
Skewness Style +1.09 -4.39% -4.81% -56.6%
Momentum Style +1.31 -4.00% -5.26% -61.9%
Historical Volatility Style +0.60 -14.00% -8.33% -98.1%
Specific Specific — — -10.88% -128.1%

3. Risk attribution

Annualised volatility is 32.39%; factor risk explains 61.6% of variance and specific risk 38.4%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-41.4-20.7+0.0+20.7+41.4Max Drawdown-0.50Beta-0.45Leverage (Downside Vol)+0.26Residual Volatility+0.71Non-linear Size+1.14Kurtosis+1.19Skewness+1.23Historical Volatility+3.54Mid Cap+4.07Amihud Illiquidity+5.42Size+7.86Momentum+12.59Health Care+23.97Specific+38.35
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 38.4% +12.42% 12.4%
Health Care Industry +0.98 24.0% +7.76% 7.8%
Momentum Style +1.31 12.6% +4.08% 4.1%
Size Style -1.25 7.9% +2.55% 2.5%
Amihud Illiquidity Style +1.81 5.4% +1.76% 1.8%
Mid Cap Style +1.02 4.1% +1.32% 1.3%
Historical Volatility Style +0.60 3.5% +1.15% 1.1%
Skewness Style +1.09 1.2% +0.40% 0.4%
Kurtosis Style +0.96 1.2% +0.39% 0.4%
Non-linear Size Style +1.65 1.1% +0.37% 0.4%
Residual Volatility Style +1.46 0.7% +0.23% 0.2%
Leverage (Downside Vol) Style -0.52 0.3% +0.08% 0.1%
Liquidity Style -0.10 0.2% +0.08% 0.1%
Industrials Industry +0.02 0.2% +0.06% 0.1%
Beta Style -0.17 -0.5% -0.14% -0.1%
Max Drawdown Style +0.14 -0.5% -0.16% -0.2%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.6-0.60.41.42.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.25 +2.10 -3.34
Non-linear Size +1.65 +1.68 -0.03
Mid Cap +1.02 +0.13 +0.89
Beta -0.17 +1.29 -1.47
Momentum +1.31 +0.72 +0.60
Short-term Reversal -0.11 -0.64 +0.53
Residual Volatility +1.46 -0.40 +1.86
Historical Volatility +0.59 +0.86 -0.27
Liquidity -0.10 +0.11 -0.21
Amihud Illiquidity +1.81 +1.16 +0.66
Turnover -0.14 +0.21 -0.35
Growth +0.09 +0.58 -0.50
Leverage (Downside Vol) -0.52 +0.14 -0.66
Skewness +1.09 +0.24 +0.86
Kurtosis +0.96 +0.21 +0.74
Max Drawdown +0.14 -0.08 +0.22

5. Industry allocation & Brinson

Industry allocation (weight, %)-9.819.749.278.8108.3Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 1.6% 11.1% +3.77% +4.36% -2.05% -0.07% +0.06% -0.43%
Health Care 98.4% 1.7% -9.62% +8.29% +24.58% -0.31% -17.32% -9.62%
Total +23.92% +15.95% -33.59% +6.28%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
PTGX PROTAGONIST THERAPEUTICS INC Health Care 21.73% -11.40% -2.48% Hold
ARGX ARGENX SE Health Care 20.79% -0.83% -0.17% Hold
INSM INSMED INC Health Care 10.77% +7.66% +0.83% Reduce
TNGX TANGO THERAPEUTICS INC Health Care 10.68% -3.13% -0.33% Add
RGEN REPLIGEN CORP Health Care 8.11% -15.32% -1.24% Add
GH GUARDANT HEALTH INC Health Care 8.05% -19.25% -1.55% Hold
NTRA NATERA INC Health Care 7.56% -30.20% -2.28% Reduce
MDGL MADRIGAL PHARMACEUTICALS INC Health Care 4.80% -15.87% -0.76% Reduce
GPCR STRUCTURE THERAPEUTICS INC Health Care 2.17% -40.61% -0.88% Add
TSHA TAYSHA GENE THERAPIES INC Health Care 2.01% -16.63% -0.34% Hold
DHR DANAHER CORP DEL Industrials 1.55% +3.77% +0.06% Hold
NGNE NEUROGENE INC Health Care 1.28% -16.25% -0.21% Add
BEAM BEAM THERAPEUTICS INC Health Care 0.43% -14.36% -0.06% Hold
MDLN MEDLINE INC Health Care 0.07% +12.88% +0.01% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 INSM Health Care 10.77% +7.66% +0.83%
2 DHR Industrials 1.55% +3.77% +0.06%
3 MDLN Health Care 0.07% +12.88% +0.01%
4 BEAM Health Care 0.43% -14.36% -0.06%
5 ARGX Health Care 20.79% -0.83% -0.17%
6 NGNE Health Care 1.28% -16.25% -0.21%
7 TNGX Health Care 10.68% -3.13% -0.33%
8 TSHA Health Care 2.01% -16.63% -0.34%
9 GPCR Health Care 2.17% -40.61% -0.88%
10 RGEN Health Care 8.11% -15.32% -1.24%
11 GH Health Care 8.05% -19.25% -1.55%
12 NTRA Health Care 7.56% -30.20% -2.28%
13 PTGX Health Care 21.73% -11.40% -2.48%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -8.90%, versus -17.01% for the QQQ synthetic benchmark — an excess of +8.11%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +7.19%, Health Care +6.88%, Residual Volatility +4.82%; the largest drags came from Historical Volatility -8.33%, Momentum -5.26%, Skewness -4.81%. Specific (stock-level) return contributed -10.88%.
  3. Risk attribution: Barra model volatility is 32.39% annualised; factor risk explains 62% of variance and specific risk 38%. The largest factor risk sources are Health Care 24.0%, Momentum 12.6%, Size 7.9%.
  4. Style tilt: size -1.25, momentum +1.31, volatility +0.59, liquidity -0.10; the weighted raw beta is 0.70. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+96.7 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.92%, selection +15.95% and interaction -33.59%.
  6. Concentration: the top-10 positions are 96.7% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did RTW INVESTMENTS, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, RTW INVESTMENTS, LP reported 81 equity positions worth $9.91B in aggregate; its largest disclosed positions were PTGX ($713.07M), ARGX ($682.35M), CGON ($603.60M).

How large is RTW INVESTMENTS, LP's portfolio?

RTW INVESTMENTS, LP reported $9.91B of long equity holdings across 81 positions as of 2026-Q3. Top-10 holdings account for 43.5% of reported value.

What is RTW INVESTMENTS, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/rtw-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →